I'm betting the market won't look at the numbers as you are. If it sees a 300% increase in revenue it'll be happy, PROVIDED there's a "respectable" increase in sales (and definitely NOT a decrease). So bearing in mind that the coming quarterly release is for revenue up to December and not after are you betting the revenue for the 2025Q2 will be over 5M?. AND NO, Im not taking you to be giving financial advice and no one in this forum should be taking you to be giving financial advice. Its just your bet. And if you're in the ballpark for product sales (600K), that seems respectable to me. But one thing that troubles me about FebriDx that I wouldn't mind your opinion on (or anyone else whose interested). Govts and the medical profession may care about overprescribing antibiotics but your average patient couldn't give a damn and you can bet that they'll pressure the Doc to just give me the antibiotic and we'll see. So until there's regulations that say that you have to have the test first B4 the doc prescribes the antibiotic I dont see a big market for the .FebriDx. What do you say?
LDX Price at posting:
4.1¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)